Insider Buying: Clearmind Medicine (NASDAQ:CMND) Major Shareholder Purchases 2,159,052 Shares of Stock

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt acquired 2,159,052 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The stock was purchased at an average cost of $0.15 per share, with a total value of $323,857.80. Following the transaction, the insider owned 2,063,266 shares in the company, valued at approximately $309,489.90. This trade represents a -2,254.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The shares were sold at an average price of $0.12, for a total transaction of $27,022.92.

Clearmind Medicine Price Performance

Shares of NASDAQ CMND remained flat at $3.34 during mid-day trading on Friday. 160,481 shares of the stock were exchanged, compared to its average volume of 1,154,156. The firm’s fifty day moving average is $6.37 and its 200-day moving average is $17.01. The company has a market capitalization of $3.40 million, a PE ratio of -0.02 and a beta of 0.64. Clearmind Medicine Inc. has a one year low of $2.10 and a one year high of $524.00.

Clearmind Medicine (NASDAQ:CMND) last posted its earnings results on Thursday, March 12th. The company reported ($33.20) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.